- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Human immunodeficiency virus (HIV) infection
- Meeting Date: November 2019
- Public Summary Document (PSD) November 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) November 2019 PBAC Meeting - (Word 181KB)
Darunavir with cobicistat with emtricitabine and tenofovir alafenamide – November 2019
Darunavir with Cobicistat with Emtricitabine and Tenofovir alafenamide: Tablet containing darunavir 800 mg with cobicistat 150 mg with emtricitabine 200 mg and tenofovir alafenamide 10 mg; Symtuza®
Last updated
6 March 2020